ORKA

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended September 30, 1999, for Hyseq, Inc. (Note: The request metadata listed "Oruka Therapeutics," but the filing text identifies the registrant as Hyseq, Inc.). Hyseq is a biotechnology company focused on gene discovery and sequencing technologies, operating through its wholly-owned subsidiary, GeneSolutions Inc. The company relies heavily on collaboration agreements for revenue and is engaged in significant patent litigation.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue: Contract revenues increased slightly for the three months ended September 30, 1999 ($1.49M vs. $1.35M in 1998) but decreased for the nine-month period ($5.29M vs. $6.72M in 1998). The nine-month decline is attributed to the timing of revenue recognition from collaboration partners.
• Operating Expenses: Total operating expenses decreased to $6.15 million for the quarter (from $7.57M in 1998) and $19.86 million for the nine months (from $21.08M in 1998).
  • R&D: Decreased in the quarter due to lower material consumption costs from reduced sequencing production levels during facility build-out.
  • G&A: Decreased primarily due to lower legal costs while awaiting litigation outcomes, partially offset by increased staffing and website launch costs.
• Net Loss: The net loss improved for the quarter ($4.33M vs. $5.47M in 1998) but widened for the nine months ($13.47M vs. $12.07M in 1998).
• Liquidity: Cash and cash equivalents decreased from $21.56 million at year-end 1998 to $16.37 million at September 30, 1999. Total cash and investments stood at $32.0 million.

Guidance, Outlook, Risks, and Contingencies

• Outlook: Management expects revenues from the Chiron collaboration to remain at approximately $1.4 million in Q4 1999. An expanded relationship with PE Corporation may provide up to $1.35 million in additional revenue through 2000. Operating expenses are expected to increase in Q4 due to commercialization costs for GeneSolutions and higher litigation expenses.
• Liquidity: The company expects existing capital resources and a $5.0 million asset-backed financing commitment (of which $2.3 million was drawn as of Sept 30) to fund operations through the first half of 2001. The financing commitment expires December 31, 1999, and extension is not guaranteed.
• Legal Proceedings (Material Risk):
  • Hyseq v. Affymetrix: Hyseq is suing Affymetrix for patent infringement regarding SBH technology. A claims construction order was issued in October 1999, with a trial date expected to be set in December 1999.
  • Affymetrix v. Hyseq: Affymetrix has counter-sued Hyseq for patent infringement. A trial is currently scheduled for October 2000.
  • New Litigation: In October 1999, Hyseq filed a new suit against Affymetrix alleging infringement of a recently issued patent.
• Year 2000 Compliance: The company believes its systems are Y2K compliant. Estimated costs for modifications are not expected to exceed $50,000.

Investor Verification Checklist

• Verify the status and potential financial impact of the ongoing patent litigation with Affymetrix, including the likelihood of injunctions or damages.
• Confirm the renewal status of the $5.0 million asset-backed financing commitment expiring December 31, 1999.
• Monitor the progress of the PE Corporation collaboration to validate the projected $1.35 million revenue stream.
• Assess the timeline for the commercialization of GeneSolutions Inc. and the associated increase in operating expenses.
• Review the company's ability to secure new collaboration partners to offset the high burn rate and accumulated deficit of $44.6 million.